NACS Urges Action on Retail Crime Ahead of House Judiciary Hearing – Petroleum & Convenience Marketers of Alabama

About
Membership
Become a Member
Discover the advantages of P&CMA membership, from advocacy and networking to exclusive discounts and training.
Membership Types
Whether you’re a petroleum marketer or an industry partner, P&CMA offers memberships designed to provide the support, resources, and connections you need.
Member Benefits
Discover the valuable tools, industry reports, training programs, and regulatory updates that help you navigate the evolving petroleum and convenience marketing landscape.
News & Events
In the NewsIn the News
December 19, 2025

Dash In Continues Carolina Expansion

December 19, 2025

From the Editor: My Favorite Articles of 2025

December 19, 2025

Trump Issues Executive Order to Expedite Cannabis as Schedule III Drug

December 19, 2025

NACS Supports American Franchise Act

December 19, 2025

Know a Retailer Changing the Game in Asia-Pacific?

December 18, 2025

BP Names New CEO; Pilots New Store Formats in UK

December 18, 2025

Dover Launches Retail Media Network on Fuel Dispensers

December 18, 2025

Sunoco Adds Wex Commercial Mobile Fuel Payment

December 18, 2025

Loop Neighborhood Markets Rolls Out Retail Media Network

December 18, 2025

TEI: 6 Strategies for Reducing ICE Emissions

Upcoming EventsUpcoming Events
Nothing Found
PublicationsPublications
Alabama Tank Operator Online Learning System
Oil Prophets
Training & Resources
Educational Foundation
Contact

December 17, 2025|NACS|

NACS Urges Action on Retail Crime Ahead of House Judiciary Hearing

Back to All News

NACS’s letter underscores the real-world impacts of crime on convenience retailers and the communities they serve.

About Us

Your Voice in Advocacy, Education, and Business Growth

Become a P&CMA Member

Related Posts

December 19, 2025

Dash In Continues Carolina Expansion

December 19, 2025

From the Editor: My Favorite Articles of 2025
December 19, 2025

Trump Issues Executive Order to Expedite Cannabis as Schedule III Drug